FDAnews
www.fdanews.com/articles/188199-yescartas-cost-leads-to-nice-rejection
GILEAD.gif

Yescarta’s Cost Leads to NICE Rejection

August 29, 2018

Although Gilead recently received EU approval for its CAR-T cell therapy Yescarta (axicabtagene ciloleucel), the U.K.’s National Institute for Health and Care Excellence did not find the drug to be a cost-effective use of National Health Service funds and chose not to recommend it in draft guidance.

NICE noted that the benefit of Yescarta compared to salvage chemotherapy is not known.

“Cell therapy is a new and advanced technology and, as NICE has identified, there is little available data about the salvage treatment of patients with aggressive forms of non-Hodgkin lymphoma (NHL) in England,” Gilead said. “We’re therefore in ongoing discussions with NICE to identify appropriate treatment comparators which can clarify how cell therapy may be made available to patients in the UK.”

View today's stories